Damora Therapeutics, Inc. (DMRA)
30.58
-0.04
(-0.13%)
USD |
NASDAQ |
Aug 26, 15:51
Damora Therapeutics Price to Book Value : 4.891 for Aug. 26, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 4.898 |
| August 24, 2026 | 4.848 |
| August 21, 2026 | 4.930 |
| August 20, 2026 | 4.848 |
| August 19, 2026 | 5.189 |
| August 18, 2026 | 5.087 |
| August 17, 2026 | 4.973 |
| August 14, 2026 | 4.965 |
| August 13, 2026 | 4.915 |
| August 12, 2026 | 4.959 |
| August 11, 2026 | 4.856 |
| August 10, 2026 | 4.725 |
| August 07, 2026 | 4.786 |
| August 06, 2026 | 4.780 |
| August 05, 2026 | 4.931 |
| August 04, 2026 | 4.802 |
| August 03, 2026 | 4.568 |
| July 31, 2026 | 4.637 |
| July 30, 2026 | 4.672 |
| July 29, 2026 | 4.532 |
| July 28, 2026 | 4.706 |
| July 27, 2026 | 4.709 |
| July 24, 2026 | 4.610 |
| July 23, 2026 | 4.666 |
| July 22, 2026 | 4.797 |
| Date | Value |
|---|---|
| July 21, 2026 | 5.277 |
| July 20, 2026 | 5.277 |
| July 17, 2026 | 5.035 |
| July 16, 2026 | 4.837 |
| July 15, 2026 | 4.951 |
| July 14, 2026 | 4.957 |
| July 13, 2026 | 4.479 |
| July 10, 2026 | 4.564 |
| July 09, 2026 | 4.923 |
| July 08, 2026 | 4.404 |
| July 07, 2026 | 4.799 |
| July 06, 2026 | 4.767 |
| July 02, 2026 | 4.796 |
| July 01, 2026 | 4.333 |
| June 30, 2026 | 4.160 |
| June 29, 2026 | 3.852 |
| June 26, 2026 | 4.035 |
| June 25, 2026 | 3.591 |
| June 24, 2026 | 3.500 |
| June 23, 2026 | 3.650 |
| June 22, 2026 | 3.80 |
| June 18, 2026 | 3.378 |
| June 17, 2026 | 3.408 |
| June 16, 2026 | 3.276 |
| June 15, 2026 | 3.193 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.902 |
| Alnylam Pharmaceuticals, Inc. | 23.60 |
| Anika Therapeutics, Inc. | 2.113 |
| Savara, Inc. | 7.999 |
| Vericel Corp. | 5.875 |
Price to Book Value Related Metrics
| PEG Ratio | -0.0003 |
| Price | 30.58 |
| Earnings Yield | -408.1% |
| Market Cap | 1.888B |
| PEGY Ratio | -0.0003 |